ArticleClinical research in cardiology : official journal of the German Cardiac Society2019
Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 76 citations in OpenAlex.
- A blood-based metabolomics study of cardiovascular diseases in Swedish twins reveals apolipoprotein B biology as important for myocardial infarction.GeroScience · 2026Article
- Association of apolipoprotein B, excess apolipoprotein B and apoB/apoA1 ratio with 20-year atherosclerotic cardiovascular disease risk: the ATTICA study (2002-2022).Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- The inflammatory marker SIRI acts as a statistical mediator between ApoB/ApoA1 ratio and atrial fibrillation, and combined biomarkers show higher discriminative ability for the presence of atrial fibrillation than single indicators.Frontiers in cardiovascular medicine · 2026Article
- Associations of non-traditional lipid parameters with high-risk plaques characterized by optical coherence tomography in acute myocardial infarction culprit lesions.Frontiers in cardiovascular medicine · 2026Article
- Association of the apolipoproteins with retinal arteriosclerosis in a health examination population.Frontiers in cardiovascular medicine · 2026Article
- Cardiometabolic risk profiles in subclinical hypothyroidism, and the potential impact of statin therapy: A cross-sectional and longitudinal study.Metabolism open · 2025Article
- Long-term trajectories of apolipoprotein A1 and major adverse cardiovascular events and mortality in a community cohort.Lipids in health and disease · 2025Article
- ApoB/ApoA-Ι is associated with major cardiovascular events and readmission risk of patients after percutaneous coronary intervention in one year.Scientific reports · 2025Article
- Comprehensive Quality Analysis of Conventional and Novel Biomarkers in Diagnosing and Predicting Prognosis of Coronary Artery Disease, Acute Coronary Syndrome, and Heart Failure, a Comprehensive Literature Review.Journal of cardiovascular translational research · 2024Review
- Adipocytes reprogram the proteome of breast cancer cells in organotypic three-dimensional cell cultures.Scientific reports · 2024Article
- Accurate diagnosis of severe coronary stenosis based on resting magnetocardiography: a prospective, single-center, cross-sectional analysis.Journal of geriatric cardiology : JGC · 2024Article
- Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1.Journal of lipid research · 2024Article
- Article
- Bariatric surgery, through beneficial effects on underlying mechanisms, improves cardiorenal and liver metabolic risk over an average of ten years of observation: A longitudinal and a case-control study.Metabolism: clinical and experimental · 2024Article
- ApoB100 and Atherosclerosis: What's New in the 21st Century?Metabolites · 2024Review
- Revisiting an old relationship: the causal associations of the ApoB/ApoA1 ratio with cardiometabolic diseases and relative risk factors-a mendelian randomization analysis.Cardiovascular diabetology · 2024Article
- Serum apolipoprotein B to apolipoprotein A-I ratio predicts mortality in patients with heart failure.ESC heart failure · 2024Article
- Association of High apoB/apoA1 Ratio with Increased Erythrocytes, Platelet/Lymphocyte Ratio, D-dimer, Uric Acid and Cardiac Remodeling in Elderly Heart Failure Patients: A Retrospective Study.International journal of general medicine · 2024Article
- The association of apolipoprotein in the risk of ST-elevation myocardial infarction in patients with documented coronary artery disease.International journal of cardiology. Cardiovascular risk and prevention · 2023Article
- Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease.Circulation research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe current way to assess the risk of cardiovascular disease (CVD) is to measure conventional lipid and lipoprotein cholesterol fractions. Despite the success of statin treatment, residual cardiovascular risk remains high. Therefore, the value of extensive serum apolipoprotein (apo) profiling to assess the risk of ST-segment elevation myocardial infarction (STEMI) and of major adverse cardiac events (MACE) in patients with STEMI was investigated in a case-control design. METHODS AND
resultsSerum apo levels were measured using liquid chromatography and mass spectrometry in 299 healthy individuals and 220 patients with STEMI. First, the association of apo profiles in baseline samples with risk of STEMI was examined, and second, the association of apo profiles at baseline with risk of recurrent MACE in patients with STEMI in a longitudinal study design was studied. High baseline (> 1.25 g/L) apoA1 levels were associated with a decreased risk of STEMI [odds ratio (OR) 0.17; 95% CI 0.11-0.26], whereas high apoB (> 1.00 g/L) levels (OR 2.17; 95% CI 1.40-3.36) and apoB/apoA1 ratio (OR per 1 SD (OR/SD): 2.16; 95% CI 1.76-2.65) were associated with an increased risk. Very-low-density-lipoprotein (VLDL)-associated apos gave conflicting results. Neither conventional lipid levels nor apo levels were associated with MACE in the STEMI group.
conclusionIn conclusion, apoA1, apoB, and apoB/apoA1 were strongly associated with risk of STEMI. No clear relation between VLDL-associated apos and the risk of STEMI was found. Neither baseline serum apos nor lipids predicted MACE in statin-treated patients during long-term follow-up after a first STEMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.